Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.
about
Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patientsProphylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patientsClinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes.Dapsone-induced methemoglobinemia: a primer for clinicians.Clinical use of anti-TNF therapy and increased risk of infectionsPolymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patientsMethotrexate and trimethoprim-sulphamethoxazole: extremely serious and life-threatening combination.Pathological and protective immunity to Pneumocystis infection.Dapsone-associated methemoglobinemia in a patient with slow NAT2*5B haplotype and impaired cytochrome b5 reductase activity.Colonization by Pneumocystis jirovecii and its role in disease.Management of Pneumocystis jirovecii Pneumonia in Kidney Transplantation to Prevent Further Outbreak.An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital.Is Aerosolized Pentamidine for Pneumocystis Pneumonia Prophylaxis in Renal Transplant Recipients Not as Safe as We Might Think?The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis.Epidemiological Outbreaks of Pneumocystis jirovecii Pneumonia Are Not Limited to Kidney Transplant Recipients: Genotyping Confirms Common Source of Transmission in a Liver Transplantation UnitProphylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care.Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii on the fully automated BD MAX platformCurrent understanding of Pneumocystis immunology.Laboratory Diagnosis of Infections in Cancer Patients: Challenges and Opportunities.Trimethoprim-sulfamethoxazole treatment does not reverse obstructive pulmonary changes in pneumocystis-colonized nonhuman primates with SHIV infection.Pneumocystis infection in humans: diagnosis and treatment.Pneumocystis jirovecii pneumonia in kidney transplantation.Lung transplant infection.Falsely Decreased HbA1c in a Type 2 Diabetic Patient Treated with Dapsone.Opportunistic infections complicating solid organ transplantation with alemtuzumab induction.Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.Pneumocystis jirovecii and Cystic Fibrosis in Brittany, France.Outbreak of Pneumocystis jirovecii Infection among Heart Transplant Recipients: Molecular Investigation and Management of an Inter-human Transmission.Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis.Bacterial Synthesis of Unusual Sulfonamide and Sulfone Antibiotics by Flavoenzyme-Mediated Sulfur Dioxide Capture.Lethal Pneumocystis jiroveci pneumonia 24 Years After Kidney Transplantation.Late-onset Pneumocystis jirovecii pneumonia in solid organ transplant recipients.Pneumocystis pneumonia complicating immunosuppressive therapy in Crohns disease: A preventable problem?Risk factors for Pneumocystis pneumonia after the first 6 months following renal transplantation.Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression.Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis.Pneumocystis jiroveci pneumonia and colonization in patients with advanced lung cancer.Pneumocystis jirovecii pneumonia in patients with end-stage renal disease: a comparison with the general population.Pneumocystis pneumonia in solid organ transplantation.
P2860
Q24193204-779F7B0D-9B6D-4EB5-B367-B13BE614888FQ24243871-E7508411-93B0-4717-AED3-ECCCE7E3EF63Q33856426-0911F00D-888E-4B39-A707-FA4B0053E084Q33996554-46F01ED3-C292-4929-BB10-30EA78A148E2Q34338096-5AE1F78D-41FC-49E4-9280-5CD7248DAAEEQ34348246-D103DA7C-D45B-4533-869D-BBA88E7C184FQ34632336-BC5BD196-211C-4BE8-97E2-DCDB27EE6D59Q35084980-C6D3C4C1-E890-433F-B33A-53AA89228D04Q35156818-C49BB505-3A49-4F77-8B75-765DCE83C742Q35940586-BC273CF6-9D70-4CB7-8A9F-E59EB349B6EFQ36288984-B7B0095B-6429-4913-BC9E-8EEE8DB1ABE3Q36616349-D91A0032-F8BC-49E6-BC70-417512CC4F70Q36730170-513D86B2-2282-4F00-BFDE-FD228EDED7FAQ36772325-3D692161-7667-4EA9-8E74-807141035E90Q36834775-BC887B42-1FCB-4FF9-88C3-A1544F85E220Q36948496-B5E93692-2D26-4919-BB94-F7E319E7CEAAQ36971085-618C684B-FDFF-49A7-9108-7065FDFEE621Q36984703-3E1EB358-01B4-4D5B-B8BE-2A16021CEE5BQ37363377-D3238258-90D1-4484-A02D-923AE3C7539EQ37642387-788D43F0-3C25-422A-8F9A-30D885104A30Q37762544-1CDF67ED-8EC6-421E-BFD8-07FBE38479DEQ37957313-C71E5F79-CB5A-4AC5-8926-BCE32BC58F1AQ38010486-DFB56E89-A0ED-4EFD-98C0-9091D205318AQ38237610-4C2377EF-BC3E-4186-9706-FC043C6CE6FEQ38558078-D2860E85-DB07-493A-AE3B-9CBD87F6CBF9Q38647546-9CB817EE-FCD4-4389-9FE5-B42937B02C91Q38688718-3EADFEA8-A062-4B7B-B183-B9932F41C489Q38761368-F2918E05-985C-445C-B8EB-73DB21F93117Q38786977-464E901D-4EAB-4862-91DD-AF261B77478FQ38835569-660C519F-4EB8-4002-A250-EF1E80D4A147Q38937278-889CA7E3-DFCF-4945-A901-2903EB094121Q39265885-BAE9E029-27F8-47F7-A8B1-CE7AE69DF2B4Q40080089-EC2E7760-6EC1-482B-A314-60559EF70DC1Q40174669-EEECD263-ACC1-4C44-BCC8-51D2D3E50D60Q40396288-15D2B983-1465-452A-8D2A-4F633747A07AQ41032776-87F41454-70AB-498E-9751-F59412E6815AQ41605436-ED32C817-62A5-4F4C-AFA3-15AF29EF605BQ41837588-1768CB40-E351-40E5-AAB2-B393B29EA2B9Q42201539-5FFB3857-F9A3-4BAB-A106-55C3D59F3566Q42272280-1E58BF3A-1E57-4841-8296-37AAC52C151D
P2860
Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Prevention of infection due to ...... ve immunocompromised patients.
@ast
Prevention of infection due to ...... ve immunocompromised patients.
@en
type
label
Prevention of infection due to ...... ve immunocompromised patients.
@ast
Prevention of infection due to ...... ve immunocompromised patients.
@en
prefLabel
Prevention of infection due to ...... ve immunocompromised patients.
@ast
Prevention of infection due to ...... ve immunocompromised patients.
@en
P2860
P1476
Prevention of infection due to ...... ve immunocompromised patients.
@en
P2093
Jay A Fishman
Martin Rodriguez
P2860
P304
770-82, table of contents
P356
10.1128/CMR.17.4.770-782.2004
P407
P577
2004-10-01T00:00:00Z